Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?

2.

Serper

M

,

Weinberg

EM

,

Cohen

JB

,

Reese

PP

,

Taddei

TH

,

Kaplan

DE.

Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation

.

Hepatology

.

2021

;

73

(

1

):

219

-

232

.

doi:10.1002/hep.31264

.

3.

Semmler

G

,

Pomej

K

,

Bauer

DJM

, et al.

Safety of direct oral anticoagulants in patients with advanced liver disease

.

Liver Int

.

2021

;

41

(

9

):

2159

-

2170

.

doi:10.1111/liv.14992

.

4.

Potze

W

,

Arshad

F

,

Adelmeijer

J

, et al.

Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis

.

PLoS One

.

2014

;

9

(

2

):

e88390

.

doi:10.1371/journal.pone.0088390

.

5.

Kubitza

D

,

Roth

A

,

Becka

M

, et al.

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor: rivaroxaban pharmacokinetics and pharmacodynamics in hepatic impairment

.

Br J Clin Pharmacol

.

2013

;

76

(

1

):

89

-

98

.

doi:10.1111/bcp.12054

.

6.

Koh

JH

,

Liew

ZH

,

Ng

GK

, et al.

Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis

.

Dig Liver Dis

.

2022

;

54

(

1

):

56

-

62

.

doi:10.1016/j.dld.2021.07.039

.

7.

Kim

S-A

,

Lee

JY

,

Lee

J-O

,

Bang

S-M.

Preliminary result of a pilot study of apixaban in the treatment of splanchnic vein thrombosis

.

Blood

.

2022

;

140

(

Supplement 1

):

5678

-

5679

.

doi:10.1182/blood-2022-168446

.

8.

Chen

S

,

Pürerfellner

H

,

Meyer

C

, et al.

Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients

.

Eur Heart J Cardiovasc Pharmacother

.

2022

;

8

(

4

):

336

-

345

.

doi:10.1093/ehjcvp/pvab032

.

9.

Jarboe L

,

D.A.

,

Bandikatla

S

, et al.,

Drug use evaluation of direct oral anticoagulants (DOACs) in patients with advanced cirrhosis

.

Cureus

.

2022

;

14

(

4

):

e24029

.

doi:10.7759/cureus.24029

.

10.

Afzal

A

,

Suhong

L

,

Korenblat

K

,

Sanfilippo

KM.

Modest performance of available risk prediction models when used to predict hemorrhage in patients with chronic liver disease

.

ISTH Congress

.

2022

. Abstract Number: OC 24.5.

11.

Radadiya

D

,

Devani

K

,

Brahmbhatt

B

,

Reddy

C.

Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter? - a systematic review and network meta-analysis

.

Eur J Gastroenterol Hepatol

.

2021

;

33

(

1s suppl 1

):

e50

-

e58

.

doi:10.1097/MEG.0000000000002035

.

12.

Intagliata

NM

,

Henry

ZH

,

Maitland

H

, et al.

Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation

.

Dig Dis Sci

.

2016

;

61

(

6

):

1721

-

1727

.

doi:10.1007/s10620-015-4012-2

.

13.

Hum

J

,

Shatzel

JJ

,

Jou

JH

,

Deloughery

TG.

The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis

.

Eur J Haematol

.

2017

;

98

(

4

):

393

-

397

.

doi:10.1111/ejh.12844

.

14.

Jones

K

,

Pham

C

,

Aguilar

C

,

Sheth

S.

Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis

.

Fed Pract

.

2020

;

37

(

10

):

479

-

485

.

doi:10.12788/fp.0058

.

15.

Munevar Aquite

O

,

Hayes

M

,

Beyene

K

, et al.

Bleeding risk of oral anticoagulants in liver cirrhosis

.

N Z Med J

.

2022

;

135

(

1563

):

52

-

61

.

16.

Oldham

M

,

Palkimas

S

,

Hedrick

A.

Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis

.

Ann Pharmacother

.

2022

;

56

(

7

):

782

-

790

.

doi:10.1177/10600280211047433

.